Product Images Spironolactone

This text is a product description of a film-coated tablet containing 100 mg of spironolactone, USP. The dosage and usage information can be found in the accompanying prescribing information. The tablet is stored at 20° to 25°C (68° to 77°F). It is manufactured by Camber Pharmaceuticals, Inc. for Amora Pharma Pvt. Ltd. with a contact number for US customers provided. The tablets are dispensed in tight, light-resistant, child-resistant containers according to the USP standards.*

This text is detailed information about Spironolactone tablets, USP, containing 25 mg of Spironolactone per tablet. The tablets come in a pack of 100 and are for prescription use only. Dosage and usage information can be found in the prescribing information. It is recommended to store the tablets at 20° to 25°C (68° to 77°F) and protect them from light. The product is manufactured by Camber Pharmaceuticals, Inc., and the packaging is done by Annora Pharma Pvt. Ltd. from Sangareddy, India. The text also mentions a US contact number for inquiries.*

This text is a label for Spironolactone tablets. Each tablet contains 50 mg of Spironolactone, USP, and there are 100 tablets in the container. It provides instructions to store between 20° to 25°C, protect from light, and dispense in light-resistant, child-resistant containers. The label includes manufacturer information for Camber Pharmaceuticals, Inc. and Annora Pharma Pvt Ltd. The US contact number is provided for inquiries. The text also mentions an unvarnished area and a manufacturing license number.*

This is a statistical analysis related to the comparison of Spironolactone and Placebo over a period of 48 months, involving 822 participants on Spironolactone and 841 on Placebo. The Log-rank p-value is less than 0.001, indicating a significant difference between the two groups in terms of probability.*

This is a collection of data related to heart failure patients, including information such as subgroup characteristics, age, sex, race, left ventricular ejection fraction (LVEF), heart failure severity, comorbidities such as diabetes, serum creatinine levels, medication usage (e.g., Digoxin, ACEI, Beta Blockers), and potassium levels. There is also mention of the NYHA classification and the comparative effectiveness of Spironolactone compared to Placebo.*